BrainsWay (BWAY) Competitors $9.24 +0.28 (+3.13%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends BWAY vs. AXGN, SMLR, SIBN, KIDS, TMCI, CLPT, TCMD, NNOX, DCTH, and ZIMVShould you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include AxoGen (AXGN), Semler Scientific (SMLR), SI-BONE (SIBN), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), ClearPoint Neuro (CLPT), Tactile Systems Technology (TCMD), Nano-X Imaging (NNOX), Delcath Systems (DCTH), and ZimVie (ZIMV). These companies are all part of the "medical equipment" industry. BrainsWay vs. AxoGen Semler Scientific SI-BONE OrthoPediatrics Treace Medical Concepts ClearPoint Neuro Tactile Systems Technology Nano-X Imaging Delcath Systems ZimVie AxoGen (NASDAQ:AXGN) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings. Does the media favor AXGN or BWAY? In the previous week, AxoGen had 1 more articles in the media than BrainsWay. MarketBeat recorded 2 mentions for AxoGen and 1 mentions for BrainsWay. AxoGen's average media sentiment score of 1.44 beat BrainsWay's score of 0.96 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BrainsWay 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AXGN or BWAY more profitable? BrainsWay has a net margin of 3.88% compared to AxoGen's net margin of -7.91%. BrainsWay's return on equity of 3.52% beat AxoGen's return on equity.Company Net Margins Return on Equity Return on Assets AxoGen-7.91% -14.91% -7.49% BrainsWay 3.88%3.52%2.26% Do analysts rate AXGN or BWAY? AxoGen presently has a consensus price target of $15.00, suggesting a potential downside of 4.09%. BrainsWay has a consensus price target of $13.17, suggesting a potential upside of 42.50%. Given BrainsWay's higher possible upside, analysts plainly believe BrainsWay is more favorable than AxoGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AxoGen 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00BrainsWay 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in AXGN or BWAY? 80.3% of AxoGen shares are held by institutional investors. Comparatively, 30.1% of BrainsWay shares are held by institutional investors. 7.0% of AxoGen shares are held by company insiders. Comparatively, 19.0% of BrainsWay shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher earnings and valuation, AXGN or BWAY? BrainsWay has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxoGen$180.86M3.81-$21.72M-$0.32-48.88BrainsWay$38.63M4.50-$4.20M$0.1092.40 Which has more volatility & risk, AXGN or BWAY? AxoGen has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Does the MarketBeat Community favor AXGN or BWAY? AxoGen received 385 more outperform votes than BrainsWay when rated by MarketBeat users. Likewise, 72.71% of users gave AxoGen an outperform vote while only 66.67% of users gave BrainsWay an outperform vote. CompanyUnderperformOutperformAxoGenOutperform Votes45372.71% Underperform Votes17027.29% BrainsWayOutperform Votes6866.67% Underperform Votes3433.33% SummaryBrainsWay beats AxoGen on 10 of the 17 factors compared between the two stocks. Ad DTICackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. Get BrainsWay News Delivered to You Automatically Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BWAY vs. The Competition Export to ExcelMetricBrainsWaySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$168.56M$4.34B$5.14B$9.08BDividend YieldN/A44.57%5.09%4.23%P/E Ratio92.4125.3789.9717.18Price / Sales4.5045.921,116.21116.99Price / CashN/A43.4542.8937.86Price / Book3.707.094.784.78Net Income-$4.20M$13.64M$120.23M$225.60M7 Day Performance-1.91%-2.93%-1.92%-1.23%1 Month Performance-6.10%0.28%11.49%3.36%1 Year Performance33.33%40.76%30.57%16.60% BrainsWay Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BWAYBrainsWay3.9057 of 5 stars$9.24+3.1%$13.17+42.5%+40.9%$168.56M$38.63M92.41120AXGNAxoGen0.9827 of 5 stars$14.40+1.7%$15.00+4.2%+125.0%$633.72M$180.86M-44.47426Positive NewsSMLRSemler Scientific1.301 of 5 stars$74.56+11.0%N/A+44.1%$618.10M$68.18M35.2792Gap DownHigh Trading VolumeSIBNSI-BONE4.3095 of 5 stars$13.73+2.3%$23.00+67.5%-35.2%$575.84M$138.89M-14.59350Positive NewsKIDSOrthoPediatrics3.8714 of 5 stars$22.47+1.6%$40.00+78.0%-29.8%$544.22M$148.73M-17.98200Analyst ForecastTMCITreace Medical Concepts1.7006 of 5 stars$7.51+0.1%$7.40-1.5%-36.6%$467.87M$187.12M-7.58250Analyst ForecastNews CoverageCLPTClearPoint Neuro0.45 of 5 stars$16.17+5.5%$11.33-29.9%+142.2%$446.05M$30.43M-22.21110Positive NewsTCMDTactile Systems Technology3.5784 of 5 stars$17.93+0.1%$23.00+28.3%+23.9%$430.32M$274.42M27.57980Analyst UpgradeNNOXNano-X Imaging2.3569 of 5 stars$7.34+6.5%$12.00+63.5%+2.9%$424.10M$10.68M-8.11190DCTHDelcath Systems2.8196 of 5 stars$12.93+6.8%$21.50+66.3%+212.8%$413.42M$22.64M-9.6776Gap DownZIMVZimVie2.3654 of 5 stars$13.76+0.2%$18.33+33.2%-20.6%$379.78M$457.43M-1.052,600 Related Companies and Tools Related Companies AXGN Alternatives SMLR Alternatives SIBN Alternatives KIDS Alternatives TMCI Alternatives CLPT Alternatives TCMD Alternatives NNOX Alternatives DCTH Alternatives ZIMV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BWAY) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BrainsWay Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BrainsWay With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BWAY Stock Alerts